Market Performance of In8bio Inc. (INAB)
In8bio Inc. (ticker: INAB) closed its trading session on Friday, 23 November 2026, at a price of USD 1.02. The share price fell 4.39 % during the 24‑hour period ending at 20:02 Central Europe time.
- Shares outstanding: 9.9 million
- Market capitalization: USD 10.8 million
- Volume traded in last 24 hours: USD 35.1 thousand
- 52‑week high: USD 2.73 (16 January 2026)
- 52‑week low: USD 0.88 (12 August 2026)
- 200‑day simple moving average: USD 1.50
The decline aligns with the performance observed since the end of the previous month, which also shows a 4.39 % decrease.
Comparison with Peer Stocks (Last 24 Hours)
| Stock | Ticker | % Move | Current Price (USD) | Market Cap (USD) |
|---|---|---|---|---|
| Sintx | SINT | –5.75 % | 1.63 | 12.4 million |
| Universal Safety Products | UUU | +7.98 % | 3.85 | 12.3 million |
| Innsuites Hospitality | IHT | +3.74 % | 1.14 | 12.0 million |
| Netcapital | NCPL | –22.28 % | 1.44 | 12.6 million |
| Veea | VEEA | –1.00 % | 4.83 | 12.4 million |
Recent Regulatory Filing – Innsuites Hospitality Trust
On 22 October 2026, the U.S. Securities and Exchange Commission filed a Form 4 change‑of‑beneficial‑ownership report for the Innsuites Hospitality Trust (IHT). The filing documented a transfer of more than forty thousand shares by principal shareholder Wirth James F. on 20 October 2026, finalized on 22 October. Following the transaction, the shareholder held approximately 7.5 million shares. The report confirms continued direct ownership but does not disclose additional operational or financial details.
Company Overview – In8bio Inc.
- Industry: Clinical‑stage biotechnology
- Headquarters: New York, United States
- Product focus: Therapies for cancers, including solid tumors, using allogeneic, autologous, and genetically modified gamma‑delta T cells
- Market listing: Nasdaq
- Website: www.in8bio.com
This data summarizes In8bio’s recent trading activity, market context, and relevant regulatory updates within the corporate news landscape.